The associations of liver fat content (LFC) and hepatotoxic biomarker alanine aminotransferase (ALT) with BMD have not been fully studied, and the mechanisms underlying the association between NAFLD and bone mineral loss are still not clear. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.